Expansion of the Territory Sample Clauses

Expansion of the Territory. Sankyo is hereby granted options to add Japan and the European Union (which shall mean those countries which make up the European Union as of the Effective Date and the additional countries of Norway and Switzerland) to the Territory. The options for Japan and the European Union shall individually expire on [ * ]. Should Sankyo decide to so expand the Territory, it shall provide GelTex with written notice of such decision prior to the expiration of the option, and following GelTex's receipt of such written notice, the definition of the Territory shall be revised to include the additional countries and/or territories specified in such notice. As part of its due diligence obligations Sankyo shall be required to: (i) commence Phase I clinical trials of Compound in Japan within [ * ] of adding Japan to the Territory; and (ii) file a Marketing Authorization Application in the European Union (or equivalent regulatory submissions in at least two countries of the European Union designated by the mutual agreement of the Parties) within [ * ] after the NDA for Compound is filed in the United States. If Sankyo fails to meet either of the due diligence [ * ] Confidential information omitted and filed separately with the Commission.
Sample 1Sample 2
AutoNDA by SimpleDocs
Expansion of the Territory. The parties hereby acknowledge and agree -------------------------- that, as of the Effective Date, the Territory shall be limited to the U.S. Cytogen hereby grants to Bard a right of first offer to expand the Territory to include one (1) or more of the Selected Countries, subject to relinquishment by CIS and Faulding of their respective rights of first negotiation to market and promote Product to Urologists in the Selected Countries. In the event CIS notifies Cytogen that it relinquishes its said right of first negotiation with respect to one or more of the Selected Countries (other than Canada) or in the event Faulding notifies Cytogen that it relinquishes its said right of first negotiation with respect to Canada (a "Waiver Notice"), Cytogen, within thirty (30) business days of its
Sample 1Sample 2
Expansion of the Territory. Licensor shall provide to Licensee a right of first refusal on any license proposed to be granted by Licensor to any third party for use of the Technology outside the Territory but in the Industry, affording Licensee the opportunity to extend the Territory on terms and conditions at least as favorable as those proposed to be granted under the proposed transaction. In addition, Licensor shall expand the Territory upon written request of Licensee, provided (a) Licensor has not granted rights to any third party in the geographic area requested, and (b) Licensee can make a commercially reasonable showing that that Licensee has a bona fide business opportunity in such region. In the event Licensee is not successful in consummating a sublicense of the Technology hereunder in such expanded Territory, such region shall revert to Licensor in a reasonable time.
Sample 1
Expansion of the Territory. (a) During the Term, [***] shall have [***] to obtain [***] in the [***]. Epirus shall [***] with any [***] to obtain [***] in the [***]. In the event that Epirus and Ranbaxy have [***] pursuant to which [***] such a [***] in the [***], Epirus shall [***] for the [***] in the [***].
Sample 1
Expansion of the Territory. At any time during the initial twelve (12) months of the Term of this Agreement, WYETH shall have the right and option to negotiate for the addition of countries or geographic areas to the Territory. Such right is exercisable by delivery of written notice to ACCESS, specifying the countries or geographic areas with respect to which WYETH would like to add to the Territory, and is subject to mutual agreement of the Parties. Upon receipt of such notice, the Parties shall negotiate in good faith the terms of the exclusive or non- exclusive (as the parties may mutually agree) arrangement with respect to the additional countries or geographic areas. In the event that the Parties are unable to reach agreement on such terms on or prior to the 60th day following commencement of such negotiations, ACCESS shall bear no further obligation to WYETH under this Section 2.7 with respect to the applicable countries or geographic area; provided that ACCESS shall not thereafter enter into or be a party to any arrangement, agreement, license or distribution relationship with a Third Party with respect to the Product in all or any portion of the applicable countries or geographic areas on terms and conditions in the aggregate more favorable to such Third Party than the aggregate terms and conditions offered to WYETH without first offering such aggregate terms and conditions to WYETH.
Sample 1
Expansion of the Territory. Under Section 1.60 of the Current Agreement, the Territory is defined as “the U.S., Canada, and Mexico and their respective territories, protectorates and possessions.” On the Amendment Effective Date, the Territory as defined in the Current Agreement (the “Original Territory”), and the license granted to Catalyst under Section 2.1 of the Current Agreement, shall be expanded to include, Japan and its territories, protectorates and possessions. Further, upon acceptance by the MHLW of a Japan MAA for a Licensed Product for LEMS, the Territory, and the license granted to Catalyst under Section 2.1 of the Agreement, shall be further expanded to also include all the countries in
Sample 1
Expansion of the Territory. Should the Company wish to expand the Territory to include lsrael, Cyprus and/or any other country in the Middle East, the Licensors shall favorably consider such request, provided that the Company shall grant Hadasit a right of first refusal to set up treatment centers, with the use of the Products, in any such countries.
Sample 1
AutoNDA by SimpleDocs
Expansion of the Territory. Nextel shall have the option, at anytime during the term of this Agreement, to expand the Territory subject to the terms of this Section 2.10. In the event Nextel desires to expand the Territory, then: (i) Nextel shall provide LCC with thirty (30) days prior written notice setting forth the name(s) of any additional nations to be added to the Territory and the date that Nextel first expects to use the Software in or for that nation, (ii) the monthly software license fee set forth in Exhibit B, Section 1 hereto shall be increased, effective on the first day of the month in which the expansion becomes effective, by an amount equal to [___________] times the number of computer video display terminals ("Workstations") used by Nextel in such additional nation(s) during the month prior to each monthly payment, and (iii) the monthly Support and Maintenance Fees set forth in Exhibit B, Section 2 shall be increased, effective as set forth above, by an amount equal to [______] times the number of Workstations over which either the CellCAD Software or the ANET Software is used by Nextel in such additional nation(s) during the month prior to said monthly payment.
Sample 1
Expansion of the Territory. 5.1 PharmaPrint hereby grants AHP, and AHP accepts, an option to expand the Territory to further include any countries other than the United States of America.
Sample 1

Related to Expansion of the Territory

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • COMMENCEMENT AND COMPLETION OF THE PROJECT Section 3.01 The Project

  • Development of the Project 4.1 TSP's obligations in development of the Project: Subject to the terms and conditions of this Agreement, the TSP at its own cost and expense shall observe, comply with, perform, undertake and be responsible:

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

  • Modification of the Small Generating Facility The Interconnection Customer must receive written authorization from the NYISO and Connecting Transmission Owner before making any change to the Small Generating Facility that may have a material impact on the safety or reliability of the New York State Transmission System or the Distribution System. Such authorization shall not be unreasonably withheld. Modifications shall be done in accordance with Good Utility Practice. If the Interconnection Customer makes such modification without the prior written authorization of the NYISO and Connecting Transmission Owner, the Connecting Transmission Owner shall have the right to temporarily disconnect the Small Generating Facility. If disconnected, the Small Generating Facility will not be reconnected until the unauthorized modifications are authorized or removed.

  • EXTENSION OF USE The Contract may be extended to additional States or governmental jurisdictions upon mutual written agreement between New York State (the lead contracting State) and the Contractor. Political subdivisions and other authorized entities within each participating State or governmental jurisdiction may also participate in the Contract if such State normally allows participation by such entities. New York State reserves the right to negotiate additional minimum NYS Vehicle Discounts based on any increased volume generated by such extensions.

Time is Money Join Law Insider Premium to draft better contracts faster.